Thus, the remaining current challenge in formulating with
AHA is balancing the efficacy, mildness and stability at formulation
pH levels of 3.5-4.0. This specific pH requirement is not
limited to AHA systems. It also applies to all acidic and protondonor
actives, such as kojic acid, ascorbic acid, nicotinic acid